Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary
Summary What is this summary about? Ruxolitinib (JAKAFI ® ) is a Janus kinase (JAK) 1 and JAK2 inhibitor that is approved for acute and chronic graft-versus-host disease (GVHD). The phase III REACH2 and REACH3 trials tested efficacy and safety of ruxolitinib for patients with acute and chronic GVHD,...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publishing
2026-05-01
|
| Saila: | Therapeutic Advances in Hematology |
| Sarrera elektronikoa: | https://doi.org/10.1177/20406207261442908 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|